179 Views
Z4. COVID-19 Treatment
Poster Session: COVID-19 Treatment
Neutralizing antibody therapies targeting SARS-CoV-2 have been released for emergency use authorization by the FDA. Little is published on their real-world experience. In this retrospective study we share the results of our early experience on patient outcomes from use of these neutralizing antibodies within a large healthcare system.
Methods:
We retrospectively analyzed results of a healthcare system wide program to pro-actively identify and treat COVID-19 patients with neutralizing antibody therapy.
Results:
The 449 patients identified for SARS-CoV-2 neutralizing antibody therapy during the study period were retrospectively classified as falling in one of the three groups: untreated (199), bamlanivimab (87) and casirivimab/indevimab (125) treated patients (Table 1). Reasons identified patients were not treated most commonly were patient declined (n=74), unable to be contacted (n=36), out of treatment window (n=23), asymptomatic and feeling better (n=21) or did not have transportation (n=9). Bamlanivimab infusion did not reduce emergency room (ER) visits or hospitalization compared to untreated patient within 30-days of follow up (Table 2), and among all patients treated with antibody therapy only treatment with bamlanivimab and non-white race were predictors of need for hospitalization (Table 3). Casirivimab/indevimab did reduce subsequent ER visits or hospitalization within 30 days post-infusion when compared to the untreated group. However, patients treated with either antibody therapy had lower acuity of COVID-19 disease as reflected in need for intensive care unit (ICU) stay, mechanical ventilation or death (Table 2).Table 1: Characteristics of infused vs uninfused patientsTable 2: Outcomes in treated vs untreated patients
Table 3: Risk factors for ED visits or hospitalization in infused patients
Conclusion:
Either neutralizing antibody therapy appears to markedly reduce acuity of COVID-19 disease even if patients do progress to requiring hospitalization. However, casirivimab/indevimab therapy also decreased ER visits and hospitalization suggesting better efficacy in our experience.
Christopher Polk, MD
Associate Professor
Atrium Health
Charlotte, North Carolina, United States
Disclosure: Atea (Research Grant or Support)Gilead (Advisor or Review Panel member, Research Grant or Support)Humanigen (Research Grant or Support)Regeneron (Research Grant or Support)
Anna Jacobs, MD
Resident Physician
Carolinas Medical Center - Atrium Health
Charlotte, North Carolina, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Mindy Sampson, MD
Assistant Professor
Atrium Health
Charlotte, North Carolina, United States
Disclosure: Regeneron (Grant/Research Support)
Michael Leonard, MD
Professor
Atrium Health
Charlotte, North Carolina, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Leigh Ann Medaris, MD
Infectious Diseases Attending Physician
Atrium Health
Charlotte, NC, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Christopher Branner, MD
Atrium Health
Charlotte, North Carolina, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Vineet Goel, MD
Atrium Health
Charlotte, North Carolina, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
Lisa Davidson, MD
Medical Director, Antimicrobial Stewardship
Atrium Health
Charlotte, NC, United States
Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.